P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: A spotlight on crizanlizumab

Nabin Raj Karki, Abdullah Kutlar

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the funda-mentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.

Original languageEnglish (US)
Pages (from-to)849-856
Number of pages8
JournalJournal of Pain Research
Volume14
DOIs
StatePublished - 2021

Keywords

  • Crizanlizumab
  • P-selectin
  • Pain crisis
  • Sickle cell disease

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: A spotlight on crizanlizumab'. Together they form a unique fingerprint.

Cite this